Warfarin Dose Adjustment for Subtherapeutic INR
In a patient on warfarin 30 mg daily with an INR of 1.55, increase the weekly warfarin dose by 10-20% and recheck the INR within 3-7 days. This dose (30 mg daily) is extraordinarily high and suggests either warfarin resistance, significant drug interactions, dietary vitamin K intake, or non-adherence that must be investigated.
Immediate Dose Adjustment Strategy
Increase the total weekly dose by 10-20% (from 210 mg/week to approximately 230-250 mg/week), which translates to adding roughly 3-6 mg to the weekly total 1.
Recheck INR within 3-7 days after dose adjustment, as the PT should be determined frequently when adjusting doses to ensure movement toward the therapeutic range 1.
The target INR for DVT treatment is 2.5 (range 2.0-3.0), and this patient at 1.55 remains significantly subtherapeutic and at risk for thrombus extension or recurrent VTE 1, 2.
Critical Investigation Required
This 30 mg daily dose is highly unusual and warrants immediate investigation for the following:
Warfarin resistance (acquired or inherited) should be suspected when large daily doses are required to maintain therapeutic INR 1. True genetic resistance is rare but documented 3.
Medication interactions: Numerous drugs induce CYP2C9 metabolism or increase vitamin K availability, requiring higher warfarin doses 1.
Dietary vitamin K intake: Excessive consumption of vitamin K-rich foods (leafy greens, certain oils) can antagonize warfarin effect 4.
Non-adherence: Verify the patient is actually taking the prescribed dose consistently 1.
Malabsorption: Gastrointestinal conditions affecting warfarin absorption 5.
Dosing Principles for Subtherapeutic INR
Avoid loading doses: Large loading doses increase hemorrhagic complications without providing faster protection against thrombosis 1.
Most patients require 2-10 mg daily for maintenance anticoagulation, making 30 mg daily an extreme outlier 1.
Dose adjustments should modify the total weekly dose by 5-20% depending on how far the INR is from target 5, 6.
For an INR of 1.55 (significantly below the 2.0-3.0 target), a 10-20% increase is appropriate rather than more aggressive adjustments 5.
Monitoring Strategy
Frequent INR monitoring is essential during dose titration—check INR 2-4 times weekly until stable in therapeutic range 1, 5.
Once stable, monitoring intervals can gradually extend to a maximum of 4-6 weeks 1.
Time in therapeutic range (TTR) is critical: Patients should be in therapeutic range >60% of the time for optimal efficacy and safety 1, 7.
Common Pitfalls to Avoid
Do not double the dose abruptly: Even with a subtherapeutic INR, excessive dose increases can lead to supratherapeutic INR overshoot within days 5, 6.
Do not ignore the underlying cause: At 30 mg daily, simply increasing the dose without investigating why such high doses are needed risks missing critical drug interactions, non-adherence, or other correctable factors 3.
Ensure adequate overlap with parenteral anticoagulation: If this patient recently started warfarin for acute DVT, therapeutic anticoagulation with LMWH or UFH should continue until INR is ≥2.0 for at least 24 hours on two consecutive measurements 2, 8.
Risk Assessment
This patient remains at significant risk for VTE recurrence or extension with an INR of 1.55, as therapeutic anticoagulation has not been achieved 2, 7.
The risk of recurrent symptomatic VTE is substantially higher without adequate anticoagulation (8.7 vs 2.2 per 100 person-years in inadequately vs adequately anticoagulated patients) 7.
Consider bridging with LMWH if there is concern about the time required to achieve therapeutic INR, particularly if this is early in the treatment course for acute DVT 2, 8.